secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078142
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio Q2 2025 net loss $16.0M; cash $154.5M funds through 2027
-----------------------------------------------------------------

- Cash and cash equivalents of $154.5M as of June 30, 2025, expected to fund operations through 2027.
- Q2 2025 net loss of $16.0M ($0.17 per share) vs $10.3M ($0.17 per share) in Q2 2024.
- R&D expenses rose to $8.7M (up $3.2M YoY) driven by Phase 2 studies for tibulizumab in SSc and HS.
- Initiated TibuSHIELD Phase 2 for hidradenitis suppurativa; topline data expected Q3 2026.
- Appointed Eric Hyllengren as CFO (July 2025) and Dan Becker, M.D., Ph.D. to Board (May 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925078142/0001104659-25-078142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925078142/tm2522624d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer